@accellix : CAR-T cell therapy makes headway against glioblastoma. A dual-target CAR-T design (EGFR + IL13Rα2) developed by @KitePharma collaborators at @upenn shrank tumors in 62% of patients with recurrent glioblastoma in a new trial. penntoday.upenn.edu/news/dual-targ… • TwiCopy

Accellix

@accellix

+ Follow

Bringing the Power of Flow Cytometry to the Manufacturing Floor

ID: 1358882167053406210

calendar_today08-02-2021 20:55:48

319 Tweet

57 Followers

69 Following

Accellix

@accellix

3 months ago

CAR-T cell therapy makes headway against glioblastoma. A dual-target CAR-T design (EGFR + IL13Rα2) developed by Kite, a Gilead Company collaborators at U Penn shrank tumors in 62% of patients with recurrent glioblastoma in a new trial. penntoday.upenn.edu/news/dual-targ…

thumb_up_off_alt0

chat_bubble_outline0

repeat0

shareShare